Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring

This article was originally published in The Tan Sheet

Executive Summary

CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)

You may also be interested in...

NAD: Anti-Aging Claims ‘Muted A Bit,’ But Vigilance Remains High

Anti-aging claims in the cosmetics sector show improved compliance with advertising standards overall, but the National Advertising Division remains on the lookout for potential overstatements, particularly as personal-care companies are less inclined to challenge each other than players in other industries.

CRN Support For NAD At 10 Years: 250 Ad Claim Reviews, Better Industry Image

"We hoped that it would have legs and it would last," says CRN President and CEO Steve Mister. "We thought, 'If it makes a difference, if we feel like we actually are doing something of value for the industry, we'll keep it up'."

NAD Refers Star Herbs Blood Pressure Claims To FTC

The industry self-regulation group refers My Low Press supplement claims after Star Herbs fails to offer evidence to support its advertising. Referring uncooperative firms to FTC “was one of the things that we found attractive when we created our program with the NAD,” said CRN President and CEO Steve Mister.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts